Teva Pharmaceutical Industries Limited
5 Basel Street
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Ltd. develops, produces and markets ethical drugs, generic drugs, and fine chemicals for the pharmaceutical industry and disposable products for hospitals and home care services.
1450 articles with Teva Pharmaceutical Industries Limited
Teva Finalizes Settlement with Federal Trade Commission to Resolve All Outstanding Litigation between the Parties
Teva Pharmaceutical Industries Ltd. announced a settlement with the Federal Trade Commission that will resolve all outstanding litigation between the parties.
Teva Pharmaceuticals is expecting big things from its generic EpiPen. The company snagged approval for its generic version of Mylan’s EpiPen Auto-Injector in August 2018.
Israel-based Teva Pharmaceutical is the largest generic drug company in the world. One in 10 drugs taken in the U.S. are manufactured by Teva, but as generic drug prices are forced downward, the company has struggled.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) reported results for the year and the quarter ended December 31, 2018.
CTI BioPharma Corp. announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd.
Teva Announces Launch of ALYQ™ (Tadalafil Tablets USP), a Generic Version of ADCIRCA® in the United States
Teva Pharmaceutical Industries Ltd., announced the launch of ALYQ™, a generic version of ADCIRCA®1 tablets, 20 mg in the U.S.
Teva Receives Positive Committee for Medicinal Products for Human Use (CHMP) Opinion for AJOVY® (fremanezumab) for the Prophylaxis of Migraine in Adults
If Approved, AJOVY will be the First and Only Anti-CGRP Treatment with Quarterly and Monthly Dosing Options in the European Union
Recently, in the U.S., there has been a shortage of an anti-anxiety drug, buspirone. The American Society of Health-System Pharmacists (ASHP) lists shortages, and as of Jan. 31, 2019, noted shortages of buspirone tablets manufactured by Accord Healthcare, Mylan and Teva Pharmaceutical.
This week, the U.S. Supreme Court rejected Swiss pharmaceutical company Helsinn Healthcare S.A.’s claim that Teva Pharmaceutical violated patent rights when the Israel-based company released a generic version of its anti-nausea medicine, Aloxi.
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2018 Financial Results at 8 a.m. ET on February 13, 2019
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced that it will issue a press release on its fourth quarter and full year 2018 financial results on Wednesday, February 13, 2019 at 7:00 a.m. ET.
GlaxoSmithKline, Teva, Takeda Investing in Global Sustainability Performance with the Responsible Health Initiative
Collaboration between key players in the pharmaceutical, biotechnology and healthcare fields fortifies responsible business practices and shared value within global health supply chain
Teva Pharmaceutical Industries today announced that members of management will present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 09:30AM PST (12:30PM EST).
Teva Pharmaceutical Industries Ltd. announced today that it has resolved its ongoing dispute with Amgen over Teva’s generic cinacalcet HCl product.
12/28/2018As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more.
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Elidel®1 (pimecrolimus) Cream, 1% in the U.S.
ADDING MULTIMEDIA Teva Announces FDA Approval of First and Only Digital Inhaler with Built-In Sensors – ProAir® Digihaler™ (albuterol sulfate 117 mcg) Inhalation Powder
Bluetooth® Wireless Technology, Flow Sensors and Companion Mobile Application Track Inhaler Use in People with Asthma & COPD
Teva Announces FDA Approval of First and Only Digital Inhaler with Built-In Sensors – ProAir® Digihaler™ (albuterol sulfate 117 mcg) Inhalation Powder
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved ProAir® Digihaler
Teva Announces Positive Topline Phase IIIb Results with Fremanezumab in Adults with Migraine Who Did Not Respond to Multiple Classes of Preventive Treatments
FOCUS study met all primary and secondary endpoints in both the quarterly and monthly dosing regimens in patients with chronic and episodic migraine
The U.S. Food and Drug Administration approved another biosimilar. On Friday, the regulatory agency approved Herzuma, a biosimilar to Genentech’s Herceptin developed by South Korea-based Celltrion, Inc. and Israel-based Teva Pharmaceuticals.
Celltrion and Teva Announce FDA Approval of HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®, for the Treatment of HER2-Overexpressing Breast Cancer for Certain Indications
Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved HERZUMA® (trastuzumab-pkrb), a HER2/neu receptor antagonist biosimilar to HERCEPTIN®1 (trastuzumab) for the following indications: